Table 1: Performance comparison of reaction based de novo drug design algorithms in terms ofmaximum reward achievedMethod	QED	clogP	RT	INT	CCR5ENAMINEBB	0.948	5.51	7.49	6.71	8.63RS	0.948	8.86	7.65	7.25	8.79 (8.86)PGFS	0.948	27.22	7.89	7.55	9.05PGFS+MB	0.948	27.60	7.97	7.67	9.20 (9.26)8Under review as a conference paper at ICLR 2021Table 2: Statistics of the top-100 produced molecules with highest predicted HIV scores for everyreaction-based method used and Enamine’s building blocksNOAD					AD	Scoring ∣	RT	INT	CCR5 I	RT	INT	CCR5ENAMINEBB	6.87 ± 0.11	6.32 ± 0.12	7.10 ± 0.27	6.87 ± 0.11	6.32 ± 0.12	6.89 ± 0.32RS	7.39 ± 0.10	6.87 ± 0.13	8.65 ± 0.06	7.31 ± 0.11	6.87 ± 0.13	8.56 ± 0.08PGFS	7.81 ± 0.03	7.16 ± 0.09	8.96 ± 0.04	7.63 ± 0.09	7.15 ± 0.08	8.93 ± 0.05PGFS+MB	7.81 ± 0.01	7.51 ± 0.02	9.06 ± 0.01	7.75 ± 0.04	7.51 ± 0.04	9.01 ± 0.05(a)(b)Figure 5: Comparison of the three methods: RS (blue), PGFS (orange) and PGFS+MB (green) based
Table 2: Statistics of the top-100 produced molecules with highest predicted HIV scores for everyreaction-based method used and Enamine’s building blocksNOAD					AD	Scoring ∣	RT	INT	CCR5 I	RT	INT	CCR5ENAMINEBB	6.87 ± 0.11	6.32 ± 0.12	7.10 ± 0.27	6.87 ± 0.11	6.32 ± 0.12	6.89 ± 0.32RS	7.39 ± 0.10	6.87 ± 0.13	8.65 ± 0.06	7.31 ± 0.11	6.87 ± 0.13	8.56 ± 0.08PGFS	7.81 ± 0.03	7.16 ± 0.09	8.96 ± 0.04	7.63 ± 0.09	7.15 ± 0.08	8.93 ± 0.05PGFS+MB	7.81 ± 0.01	7.51 ± 0.02	9.06 ± 0.01	7.75 ± 0.04	7.51 ± 0.04	9.01 ± 0.05(a)(b)Figure 5: Comparison of the three methods: RS (blue), PGFS (orange) and PGFS+MB (green) basedon the rewards achieved starting with the 2000 initial reactants from a fixed validation set.
Table 3: Performance comparison of de novo drug design algorithms in terms of maximum rewardachievedMethod	QED	clogP	RT	INT	CCR5ENAMINEBB	0.948	5.51	7.49	6.71	8.63RS	0.948	8.86	7.65	7.25	8.79 (8.86)GCPN	0.948	7.98	7.42(7.45)	6.45	8.20(8.62)JT-VAE	0.925	5.30	7.58	7.25	8.15 (8.23)MSO	0.948	26.10	7.76	7.28	8.68 (8.77)PGFS	0.948	27.22	7.89	7.55	9.05PGFS+MB	0.948	27.60	7.97	7.67	9.20 (9.26)Table 4: Statistics of the top-100 produced molecules with highest predicted HIV scores of de novodrug design algorithms and Enamine’s building blocksNO AD					AD	Scoring	RT	INT	CCR5	RT	INT	CCR5ENAMINEBB	6.87 ± 0.11	6.32 ± 0.12	7.10 ± 0.27	6.87 ± 0.11	6.32 ± 0.12	6.89 ± 0.32RS	7.39 ± 0.10	6.87 ± 0.13	8.65 ± 0.06	7.31 ± 0.11	6.87 ± 0.13	8.56 ± 0.08GCPN	7.07 ± 0.10	6.18 ± 0.09	7.99 ± 0.12	6.90 ± 0.13	6.16 ± 0.09	6.95* ± 0.05JTVAE	7.20 ± 0.12	6.75 ± 0.14	7.60 ± 0.16	7.20 ± 0.12	6.75 ± 0.14	7.44 ± 0.17MSO	7.46 ± 0.12	6.85 ± 0.10	8.23 ± 0.24	7.36 ± 0.15	6.84 ± 0.10	7.92* ± 0.61PGFS	7.81 ± 0.03	7.16 ± 0.09	8.96 ± 0.04	7.63 ± 0.09	7.15 ± 0.08	8.93 ± 0.05
Table 4: Statistics of the top-100 produced molecules with highest predicted HIV scores of de novodrug design algorithms and Enamine’s building blocksNO AD					AD	Scoring	RT	INT	CCR5	RT	INT	CCR5ENAMINEBB	6.87 ± 0.11	6.32 ± 0.12	7.10 ± 0.27	6.87 ± 0.11	6.32 ± 0.12	6.89 ± 0.32RS	7.39 ± 0.10	6.87 ± 0.13	8.65 ± 0.06	7.31 ± 0.11	6.87 ± 0.13	8.56 ± 0.08GCPN	7.07 ± 0.10	6.18 ± 0.09	7.99 ± 0.12	6.90 ± 0.13	6.16 ± 0.09	6.95* ± 0.05JTVAE	7.20 ± 0.12	6.75 ± 0.14	7.60 ± 0.16	7.20 ± 0.12	6.75 ± 0.14	7.44 ± 0.17MSO	7.46 ± 0.12	6.85 ± 0.10	8.23 ± 0.24	7.36 ± 0.15	6.84 ± 0.10	7.92* ± 0.61PGFS	7.81 ± 0.03	7.16 ± 0.09	8.96 ± 0.04	7.63 ± 0.09	7.15 ± 0.08	8.93 ± 0.05PGFS+MB	7.81 ± 0.01	7.51 ± 0.02	9.06 ± 0.01	7.75 ± 0.04	7.51 ± 0.04	9.01 ± 0.05Figure 7: Comparison of the PGFS (blue) and PGFS+MB (orange) based on the maximum rewardachieved in each episode during the course of trainingFigure 8: A visualization of synthesis path for generating highest reward molecule (obtained usingPGFS+MB) against HIV-RT target18Under review as a conference paper at ICLR 2021Figure 9: A visualization of synthesis path for generating highest reward molecule (obtained usingPGFS+MB) against HIV-INT targetFigure 10: A visualization of synthesis path for generating highest reward molecule (obtained using
